RNAM - Avidity Biosciences, Inc.

72.82
0.020   0.027%

Share volume: 16,757,238
Last Updated: 02-26-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$72.80
0.02
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 43%
Dept financing 20%
Liquidity 58%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0.14%
3 Months
1.79%
6 Months
50.24%
1 Year
154.97%
2 Year
286.11%
Key data
Stock price
$72.82
P/E Ratio 
0.00
DAY RANGE
$72.75 - $73.04
EPS 
-$4.56
52 WEEK RANGE
$21.51 - $73.06
52 WEEK CHANGE
$146.43
MARKET CAP 
10.868 B
YIELD 
N/A
SHARES OUTSTANDING 
155.150 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-08-2025
BETA 
1.68
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$5,292,830
AVERAGE 30 VOLUME 
$3,628,502
Company detail
CEO: Sarah Boyce
Region: US
Website: aviditybiosciences.com
Employees: 190
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Avidity Biosciences, Inc. engages in the development of oligonucleotide-based therapies. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the. treatment of Duchenne Muscular Dystrophy.

Recent news